Clinical Outcomes Beyond 1L EGFR -TKI Progression in mNSCLC: Final Results of the Real-World Study 'LUNGFUL'.

Mutational status and treatment strategy were identified as critical determinants of clinical outcomes in the 2L-setting of EGFR-mutated NSCLC patients in real-world settings in Greece, with early diagnosis, appropriate molecular testing and high-efficacy treatments at first lines positively affecting ORR and PFS.